CNBC's "Fast Money" Would You Rather?: Goldman Sachs or The Mag7… And Structure Therapeutics CEO 1/15/26
15 snips
Jan 15, 2026 Goldman Sachs is hitting new highs as it surpasses earnings predictions, while the Mag7 faces market challenges. The discussion dives into weight loss drugs, with a spotlight on a new GLP-1 pill and its competitive landscape. Insights on regional banks versus money center banks shed light on potential investment opportunities for 2026. Additionally, the impact of a possible Spotify price hike on subscribers and the dynamic challenges in the obesity drug market are thoroughly explored.
AI Snips
Chapters
Transcript
Episode notes
Goldman Sachs Outrunning Big Tech
- Goldman Sachs is currently outperforming the MAG-7 on earnings and re-rating potential driven by investment banking strength.
- Several Fast Money traders argued cyclical bank upside could beat growth names if macro remains stable.
Rotate Into Banks During M&A Tailwind
- Favor banks while M&A and capital-markets activity remain strong and the yield curve supports trading revenues.
- Consider owning regionals too as re-rating could spread from money centers to smaller banks.
Cyclicality Versus Durable Growth
- Banks are cyclical and can show huge earnings swings in downturns compared with mature tech growth names.
- The trade-off is macro sensitivity: banks win if the economy holds, but lose more in systemic contraction.